<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Cardiology Product Guide &#187; death</title>
	<atom:link href="http://blog.cardiologyproductguide.com/tag/death/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.cardiologyproductguide.com</link>
	<description>A comprehensive guide to cardiology products for medical professionals </description>
	<lastBuildDate>Tue, 14 Jun 2011 11:39:11 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>FDA approves Boehringer Ingelheim MICARDIS</title>
		<link>http://blog.cardiologyproductguide.com/2009/10/20/fda-approves-boehringer-ingelheim-micardis/</link>
		<comments>http://blog.cardiologyproductguide.com/2009/10/20/fda-approves-boehringer-ingelheim-micardis/#comments</comments>
		<pubDate>Tue, 20 Oct 2009 07:11:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Diagnostics & Theraputics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[ACE inhibitors]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[cardiovascular causes]]></category>
		<category><![CDATA[cardiovascular problems]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[heart attack]]></category>
		<category><![CDATA[MICARDIS]]></category>
		<category><![CDATA[stroke]]></category>
		<guid isPermaLink="false">http://www.cardiologyproductguide.com/blog/?p=168</guid>
		<description><![CDATA[The FDA approves Boehringer Ingelheim&#8217;s MICARDIS® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors. This new indication is based on The ONTARGET Trial results which showed that MICARDIS® may [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.cardiologyproductguide.com/files/2009/10/Micardis.png"><img class="alignright size-full wp-image-169" style="margin: 5px" src="http://blog.cardiologyproductguide.com/files/2009/10/Micardis.png" alt="Micardis" width="200" height="64" /></a>The FDA approves Boehringer Ingelheim&#8217;s MICARDIS® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors. This new indication is based on The ONTARGET Trial results which showed that MICARDIS® may prevent one in five serious CV events or death from cardiac causes.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.cardiologyproductguide.com/2009/10/20/fda-approves-boehringer-ingelheim-micardis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

